Kawasaki disease (KD) is a vasculitis that mostly occurs in young children and rarely in adults. We analyzed the characteristics of adult-onset KD (AKD) in France.
Introduction
Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute necrotizing vasculitis of the medium and small-sized arteries with severity related to coronary aneurysm [1] . First described in Japan in 1967 [2] , KD occurs in both endemic and communitywide epidemic forms in children of all races [3, 4] . A genetic susceptibility has been identified by genome-wide association study (GWAS), but to date, the pathophysiology remains unclear [5] .
Adult-onset KD (AKD) is rare and often misdiagnosed. A recent review including post-infectious cases described 100 cases of AKD [6] . Most reports were of 1 or 2 cases, and data were often missing, especially for infectious disease investigations as a differential diagnosis, detection of coronary abnormalities and long-term outcome. Although AKD is rare, it can be devastating, and many questions remain regarding its optimal management, especially treatment with intravenous immunoglobulin (IVIg) with late diagnosis.
To improve our knowledge and management of AKD, we report a series of AKD from France.
Methods:
First, we searched for case reports of AKD in France that were published in English and/or French from 1967 (when KD was first described) through July 2015 in MEDLINE via PubMed and the National Library of Medicine. Then we contacted the authors of the reports for approval to include the cases in this report. Furthermore, we searched for other cases in We included cases that fulfilled the international diagnosis criteria for KD [7] . A complete diagnosis is defined by the presence of unexplained fever >5 days and 4 of the 5 main clinical features: 1) extremity changes starting with edema or erythema progressing to desquamation of feet and hands 2) polymorphous exanthema, 3) bilateral conjunctivitis without exudates, 4) oral changes including injected pharynx or lips, and 5) cervical lymphadenopathy >1.5 cm. Incomplete KD is defined by 3 of the above 5 criteria and coronary artery disease. To be included in this AKD series, patient had to have onset of manifestations after the age of 18 years.
We [9] and Birmingham Vasculitis Activity Score (BVAS) [10] at diagnosis and at latest news were retrospectively determined and analyzed.
Coronary vasculitis was defined by at least one of the following features: CT and CT angiography findings of concentric mural thickening of the artery wall and in the venous phase, presence of a "double ring" enhancement pattern [11] ; ultrasonography or echocardiography findings of a hyperechogenic artery wall [7, 11] ; and MRI findings of
thickened artery wall in T1 or T2 echo-spin images and presence of wall edema in short tau inversion recovery images [11] . Aneurysm was defined by an increase in artery caliber as compared with adjacent segments and loss of parallelism of the artery wall [11] . Early treatment was defined by IVIG infusion before day 9 after AKD onset and late treatment was defined by IVIG infusion after day 10 of onset. We compared early treatment and late or no treatment.
Statistical analysis
The 
Results
We collected 56 patients of AKD; 13 were excluded because of unknown HIV serology (n=5) [12] [13] [14] [15] [16] ; presence of ankylosing spondylitis associated with an atypical evolution (n=1) [17] ; recurrent palmo plantar psoriasis (n=1); KD case associated with Chikungunya infection (n=1) or Streptococcus infection (n=1); incomplete cases without coronary artery disease (n=2) and unknown age of onset (n=1) or age< 18 years (n=1). Within the remaining 43 AKD patients, 28 (65%) were reported in the literature [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . AKD diagnosis was complete for 79% of patients (n=34) and incomplete for 21% (n=9) ( Table 1 ). The cases were diagnosed between 1992 and 2015 in 26 different French centers ( Figure 1 ). Internal medicine departments were the most represented (58% of cases); 21% of cases were diagnosed by cardiologists, 12% by dermatologists, 7% by infectious diseases specialists and 2% in intensive care unit.
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ACCEPTED MANUSCRIPT 6 The mean (SD) age at diagnosis was 31 (11) years (range . The male to female ratio was 1.2. All patients were living in France but had various ethnic backgrounds: 26/43
were Caucasian (60%), 7 were from Africa (16%), 2 were from the Caribbean (5%), 1 was from Asia (2%) and 1 was from the Middle East (2%); data were not available for 6 (14%). and erythema multiform (patient 29).
Clinical characteristics (Table 2) The median time from AKD to diagnosis was 13 days (IQR 8-21; range 0-3280). Fourtyseven % of the cases (n=20) showed a seasonal peak in disease onset between October and February ( Figure 2 ). AKD clinical manifestations included fever (100%) that lasted a median of 13 days (IQR 10-18; range 4-64), changes in the extremities (91%) with peeling (77%) after a median delay of 13 days (IQR 11-17; range 2-45), hands and feet edema (61%) and extremity rash (74%). Apart from extremity rash, diffuse exanthema was present in 98% of cases and described in 81%: measles-like (47%), scarlatiniform (16%), polymorphous (9%), transient (7%) and rubella-like (2%). Patients also showed oral mucosa and lip changes (91%) with oropharyngeal injection (61%), dry fissured lips (72%), strawberry tongue (47%);
bilateral non-exudative conjunctivitis (81%) and cervical lymphadenopathy (56%). Cardiac
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7 manifestations were reported in 44% of cases: chest pain (23%), cardiogenic shock (5%), left (9%) and right heart failure (5%). The mean (SD) initial BVAS was 8 (4) (range 3-18).
On admission, median C-reactive protein level was 205 mg/L (IQR 104-298; range 54-540) and first-hour erythrocyte sedimentation rate was 70 mm (IQR 48-90; range 4-112).
Other biological abnormalities are in Table 3 .
Cardiovascular findings at diagnosis
Cardiac involvement was screened in all patients by echocardiography (93%), coronary CT Patients with early IVIg treatment versus late or no treatment did not differ in frequency of LVV (33% vs 35%, p=1) but did differ in fever duration: median 10 days (IQR 8-11; range 4-12) versus 16 (IQR 11-21; range 5-64) (p=0.002) ( Table 4 ). The initial BVAS
was significantly lower in the early than late or no treatment group: median 4 (IQR 3-6.5; range 3-13) versus 9 (IQR 5-11; range 3-18) in late or no treatment group (p=0.006) ( Table 4 ).
Most patients (86%) received aspirin: 24 (56%) had an anti-inflammatory dose and 24
(56%) an anti-aggregant dose; 23 (53%) received IVIg plus aspirin at an anti-inflammatory dose. In the early-treated group, 83% of patients received aspirin at an anti-inflammatory dose versus 45% in the late or untreated group (p=0.04). The other anti-inflammatory drugs used were steroids (14%), non-steroidal anti-inflammatory drugs (7%) and colchicine (5%). The use of cardiovascular drugs was reported for 28% of patients and included curative anticoagulation (12%) (without reported hemorrhage), angiotensin-converting enzyme inhibitors (16%), beta-blockers (12%), spironolactone (5%) and amiodarone (2%).
The median duration of follow-up after diagnosis was 5 months (IQR 2-19; range 1-117) and seems higher for patients with than without LVV: median 11 months (IQR 4-22;
range 1-117) versus 4 (IQR 2-13; range 1-78) (p=0.14). After 6 months, the proportion of coronary aneurysm detected by cardiac imaging decreased from 19% to 14% and to 9% at the end of the follow-up. The median BVAS decreased to 0 (range 0-6) at the end of follow-up.
Late complications included bilateral lower-limb ischemia with gangrene requiring a trans-metacarpal-level amputation in 1 patient (2%) and heart failure at the end of follow-up in 2 patients (5%). The median VDI was 0 (IQR 0-1, range 0-6). The VDI was significantly lower with early than late or no treatment: median 0 (range 0-1) versus 0 (range 0-6) for cases with late or no treatment (p=0.01) ( Table 4 ). No death was reported but one untreated patient relapsed after 1 month (patient 25).
Discussion
We report here the largest series of patients with adult-onset KD. These patients had a high frequency of cardiac involvement and complications, and MI and damage may be less
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10 frequent with early IVIg treatment than late or no treatment. These results seem similar to those found for childhood KD (CKD) [7] .
The BVAS and VDI are commonly used in adult vasculitis monitoring. In children, these scores are modified as the Pediatric Vasculitis Activity Score (PVAS) [34] and Pediatric VDI (PVDI) [35] , respectively, but are not yet used in KD.
Our literature search of AKD found 25 infections mimicking KD: post-HIV infection (n=20) [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] , Epstein-Barr virus infection (n=1) [50] , Streptococcus infection (n=2) [51] ,
Coxiella infection (n=1) [52] and Chikungunya infection (n=1). In our literature analysis, we did not include complications of known or suspected KD in childhood, infectious cases The American Heart Association diagnostic criteria seem applicable for AKD, with the complete form being the most frequent. Most of the incomplete cases were diagnosed by the presence of coronary vasculitis. A few cases were retrospectively diagnosed after MI complicating coronary aneurysm [26, 33] , as observed in this series.
AKD clinical signs appeared comparable to those for CKD, but the frequency of clinical signs could differ between the 2 groups. In the pediatric study of Saundankar et al., in 2014[107] , the frequency of signs we found were similar to that cited for adult polymorphous exanthema (98% vs 96%). Coronary aneurysm in our adult patients with late or no treatment seemed as prevalent as in children (19% vs 15-25% [7, 108] ). Some symptoms less common for adults than children included oropharynx changes (91% vs 96%). lymphadenopathy (56% vs 63%), conjunctivitis (81% vs 89%) and gastrointestinal symptoms (56% vs 60%), whereas
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ACCEPTED MANUSCRIPT 11 symptoms more common for adults than children were changes in extremities (91% vs 76%) and arthritis (42% vs 28%). AKD disease appears to share other features with CKD such as pericarditis, myocarditis, cardiac shock and neurological manifestations such as aseptic meningitis 5 . In addition, adult biological findings were similar to those found in children, with a marked increase in acute-phase reactants, delayed thrombocytosis, hyponatremia, hepatic cytolysis and aseptic leukocyturia [7] . We found 16% hypereosinophilia in our adult cases with 36% reported in CKD [109, 110] . In the extra-tropical latitudes of the northern hemisphere, a winter peak in CKD has been long observed [111] . To our knowledge, this is the first time the same seasonal pattern has been highlighted in AKD.
Given the exceptional nature and the need to rule out many differential diagnoses, the diagnosis of AKD is late and probably underdiagnosed. The differential diagnosis of AKD [8, 33] . Hence, the diagnostic delay is longer for AKD than CKD, for which it is usually <7 days [7] . In addition, physicians must consider cardiovascular risk factors during the acute phase of AKD to avoid further cardiovascular complications due to the development of atherosclerosis [112] .
In general, AKD is less treated than CKD [113] . IVIg was given for only 79% of our adult cases and was combined with aspirin at an anti-inflammatory dose for 53%.
Undertreatment of AKD can be explained by the natural history of the disease, which can vanish spontaneously without treatment, and by the absence of treatment standardization in cases diagnosed after 10 days of fever. However, even when administered late, IVIg seemed effective to control fever in 91% of patients, but vasculitis is not 100% preventable. For 21%
ACCEPTED MANUSCRIPT 12 of cases, late diagnosis and the absence of a gold standard treatment was associated with a higher coronary aneurysm rate as compared with well-treated CKD [7] . Of note, the initial cardiac event rate was high, with 44% cardiac impairment and 44% abnormal echocardiography findings. The presence of extracoronary vasculitis in CKD is rarely described [114] , as compared with 5% of our AKD cases.
Given the severity of coronary aneurysm, all patients, especially those with cardiac manifestations, should be screened for coronary vasculitis. Most of our cases of incident coronary aneurysm (86%) were diagnosed by coronary angiography or coronary CT angiography. Considering the limitations of echocardiography to entirely view coronary arteries in adults, this screening should include, in addition to echocardiography, coronary angiography, coronary CT angiography and/or cardiac MRI [115] . However, coronary angiography is not the best morphological exam for coronary injury screening. Coronary angiography detects later and more severe injuries such as stenosis, aneurysm and thrombosis.
It does not seem able to detect early wall-artery injuries that are more easily seen by coronary CT angiography [116] or echocardiography [117] .
Although the pathophysiology of KD is becoming better understood, specifically the genetics mechanism [118] , it still remains unclear. Recently, GWAS revealed an association of many genes: the ITPKC gene implicated in negative regulation of T cells via an NFAT pathway [119] and the FcRg2a gene associated with susceptibility to KD and also linked to IVIg response [120] . Genetic polymorphism might explain why the risk of KD could be delayed in adults. There is also a better understanding of the inflammation process: HMGB1 could get involved in KD by amplifying the inflammation [121] .
Although original, our study remains limited by its retrospective design, which prevented an exhaustive collection of data, and by a probable selection bias toward the most severe cases. Indeed, cardiovascular manifestations may be the symptom suggesting a diagnosis of KD among adult physicians, and lead to a possible overestimation of this complication in this age group. 
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